MA29377B1 - Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif - Google Patents

Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif

Info

Publication number
MA29377B1
MA29377B1 MA30266A MA30266A MA29377B1 MA 29377 B1 MA29377 B1 MA 29377B1 MA 30266 A MA30266 A MA 30266A MA 30266 A MA30266 A MA 30266A MA 29377 B1 MA29377 B1 MA 29377B1
Authority
MA
Morocco
Prior art keywords
treatment
pyrimidine derivatives
hyperproliferative disorders
compounds
cancer
Prior art date
Application number
MA30266A
Other languages
English (en)
Inventor
Julie A Dixon
Dhanapalan Nagarathnam
Lei Zhang
Chunguang Wang
Lin Yi
Yuanwei Chen
Jianqing Chen
Brian R Bear
Michael Brands
Alexander Hillisch
Donald Bierer
Ming Wang
Wenlang Fu
Martin F Hentemann
Ann-Marie Bullion
Manoj Patel
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36624969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29377(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA29377B1 publication Critical patent/MA29377B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L¿INVENTION CONCERNE DES DÉRIVÉS DE LA PYRIMIDINE DE FORMULE (I), DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSÉS, ET DES MÉTHODES D¿UTILISATION DE CES COMPOSÉS DANS LE TRAITEMENT DE MALADIES À CARACTÈRE HYPERPROLIFÉRATIF COMME LE CANCER.
MA30266A 2005-03-10 2007-10-02 Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif MA29377B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66056105P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
MA29377B1 true MA29377B1 (fr) 2008-04-01

Family

ID=36624969

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30266A MA29377B1 (fr) 2005-03-10 2007-10-02 Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif

Country Status (23)

Country Link
US (1) US20110098301A1 (fr)
EP (1) EP1858882A1 (fr)
JP (1) JP2008533042A (fr)
KR (1) KR20080004488A (fr)
CN (1) CN101151258A (fr)
AR (1) AR053554A1 (fr)
AU (1) AU2006223199A1 (fr)
BR (1) BRPI0609022A2 (fr)
CA (1) CA2601257A1 (fr)
CR (1) CR9347A (fr)
DO (1) DOP2006000061A (fr)
EA (1) EA200701930A1 (fr)
GT (1) GT200600105A (fr)
IL (1) IL185498A0 (fr)
MA (1) MA29377B1 (fr)
MX (1) MX2007010102A (fr)
NO (1) NO20074964L (fr)
PE (1) PE20061067A1 (fr)
TN (1) TNSN07322A1 (fr)
TW (1) TW200724537A (fr)
UY (1) UY29414A1 (fr)
WO (1) WO2006099231A1 (fr)
ZA (1) ZA200708591B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109275A2 (fr) * 2006-03-20 2007-09-27 Bayer Healthcare Llc. Combinaison de paclitaxel
BRPI0813629A2 (pt) * 2007-07-26 2018-07-10 Novartis Ag derivados de pirimidina úteis no tratamento de condições inflamatórias ou alérgicas
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
WO2012085815A1 (fr) 2010-12-21 2012-06-28 Novartis Ag Composés bi-hétéroaryles en tant qu'inhibiteurs de vps34
US9139534B2 (en) 2011-04-22 2015-09-22 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
NZ746607A (en) 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
WO2015076800A1 (fr) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Inhibiteurs de bmi-1 à base de pyridine et de pyrazine substituées
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US9638690B2 (en) 2014-11-07 2017-05-02 The University Of British Columbia Compounds and compositions for use as alkylating agent sensors and methods of use thereof
EP3250557B1 (fr) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
CN107922287B (zh) 2015-07-24 2021-04-09 细胞基因公司 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
TWI609028B (zh) 2016-05-06 2017-12-21 財團法人工業技術研究院 共聚物與含其之樹脂組合物、封裝膜及封裝結構
EP3836932A2 (fr) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Méthode de traitement du cancer du pancréas
CN111518078B (zh) * 2020-05-30 2021-02-26 南方医科大学 一种含氨基吡啶的嘧啶类化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3089480B2 (ja) * 1990-09-20 2000-09-18 ソニー株式会社 フリットシール装置
EP1470121B1 (fr) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Derives pyrimidine en tant qu'inhibiteurs de kinase rho
MXPA04007196A (es) * 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
WO2005035507A2 (fr) * 2003-10-10 2005-04-21 Bayer Pharmaceuticals Corporation Derives de pyrimidine dans le traitement de troubles hyperproliferatifs

Also Published As

Publication number Publication date
IL185498A0 (en) 2008-01-06
MX2007010102A (es) 2007-10-12
EA200701930A1 (ru) 2008-02-28
CN101151258A (zh) 2008-03-26
TNSN07322A1 (en) 2008-12-31
PE20061067A1 (es) 2006-11-30
EP1858882A1 (fr) 2007-11-28
JP2008533042A (ja) 2008-08-21
CR9347A (es) 2007-12-17
BRPI0609022A2 (pt) 2010-01-12
ZA200708591B (en) 2009-01-28
AU2006223199A1 (en) 2006-09-21
AR053554A1 (es) 2007-05-09
DOP2006000061A (es) 2006-09-30
US20110098301A1 (en) 2011-04-28
UY29414A1 (es) 2006-10-02
KR20080004488A (ko) 2008-01-09
NO20074964L (no) 2007-12-06
GT200600105A (es) 2007-02-14
WO2006099231A1 (fr) 2006-09-21
TW200724537A (en) 2007-07-01
CA2601257A1 (fr) 2006-09-21

Similar Documents

Publication Publication Date Title
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA29926B1 (fr) Derives de pyrazine
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA31419B1 (fr) Derives de pyridine
TNSN08359A1 (fr) Derives d'amines
MA34559B1 (fr) Formulation pour le traitement du cancer
MA32014B1 (fr) Composes condenses de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
TNSN04164A1 (fr) Inhibiteurs de acc.
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
NO20090321L (no) Anvendelse av substituerte 2-aminotyetraliner for produksjon av et medikament for forhindringen, lettingen og/eller behandlingen av diverse typer smerte
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA31022B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
TNSN07022A1 (fr) Derives de pyridine
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer